Steffen Wilhem Heeger - 03 Sep 2026 Form 3 Insider Report for Actinium Pharmaceuticals, Inc. (ATNM)

Reporting relationship: Chief Medical Officer
Issuer ticker: ATNM
Reported as of: 03 Sep 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 10 Sep 2026, 17:00:02 UTC
Source filing: View source filing
Reporting owner signature: /s/ Steffen Heeger

Filing notes and source

Key filing fact

Steffen Wilhem Heeger filed Form 3 for Actinium Pharmaceuticals, Inc. (ATNM) on 10 Sep 2026.

Key facts

This page summarizes Steffen Wilhem Heeger's Form 3 filing for Actinium Pharmaceuticals, Inc. (ATNM).
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 10 Sep 2026, 17:00.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002154146 Primary reporting owner

Heeger Steffen Wilhem

Relationship: Chief Medical Officer
Address: C/O ACTINIUM PHARMACEUTICALS, INC., 100 PARK AVE., 23RD FLOOR, NEW YORK
Signature: /s/ Steffen Heeger
Signature date: 10 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ATNM holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 153,868
Date: 03 Sep 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ATNM holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 03 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 250,000
Exercise price: $1.15
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock units ("RSUs"). The RSUs vest fully on September 2, 2029.

Footnote F2

28% of the stock options vest and become exercisable on May 28, 2027, with the remainder vesting and becoming exercisable in 36 equal monthly tranches thereafter.